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Abstract
Introduction: Anti-citrullinated protein/peptide antibodies (ACPAs) are highly specific to rheumatoid arthritis (RA)
patients and are thought to have a close relationship with the pathogenesis of arthritis. Several proteins, including
fibrinogen, vimentin, and alpha-enolase, were reported as ACPA-target antigens, and their importance in RA
pathogenesis was widely proposed. We identified citrullinated immunoglobulin binding protein (citBiP) as another
ACPA target in RA patients and examined its pro-inflammatory role in arthritis.
Methods: We measured the levels of anti-citBiP, anti-BiP, and anti-cyclic citrullinated peptide (CCP) antibodies in
the serum of RA patients (n = 100), systemic lupus erythematosus (SLE) patients (n = 60), and healthy controls (n =
30) using ELISA and immunoblotting. Epitope mapping was performed using 27 citBiP-derived peptides. In the
mouse study, after DBA/1J mice were immunized with BiP or citBiP, serum titers of ACPAs were measured by ELISA
and immunohistochemistry. The development of collagen-induced arthritis (CIA) was observed in BiP- or citBiP-pre-
immunized mice.
Results: The serum levels of anti-BiP and anti-citBiP antibodies were significantly increased in RA patients, although
only anti-BiP antibodies were slightly increased in SLE patients. Interestingly, anti-citBiP antibody levels were higher
than anti-BiP antibody levels in 72% of RA patients, whereas no significant increase in anti-citBiP antibody levels
was detected in SLE patients and healthy controls. The serum levels of anti-CCP antibodies were correlated with
those of anti-citBiP antibodies in RA patients (R
2 = 0.41). Several citrulline residues of citBiP were determined to be
major epitopes of anti-citBiP antibodies, one of which showed cross-reactivity with CCP. Immunization of DBA/1J
mice with citBiP induced several kinds of ACPAs, including anti-CCP and anti-citrullinated fibrinogen antibodies.
Pre-immunization with citBiP exacerbated CIA, and anti-CCP antibody levels were increased in citBiP-pre-immunized
CIA mice.
Conclusions: CitBiP is a newly described ACPA target that may play a pro-inflammatory role in arthritis.
Introduction
Rheumatoid arthritis (RA) is described as a chronic
inflammation of multiple joints with destructive pro-
cesses and is characterized by sustained synovitis, pan-
nus proliferation, and destruction of the cartilage and
bones. Many inflammatory processes participate in the
pathogenesis of RA, and autoimmune responses are
considered fundamental abnormalities in RA [1]. Auto-
antibodies such as rheumatoid factor (RF) are detected
in the serum and synovial fluid of RA patients. Although
the sensitivity of RF in diagnosing RA is 30%-70% in
early cases and 80%-85% in progressive cases, the speci-
ficity of RF is ~40% [2]. Recently, anti-citrullinated pro-
tein/peptide antibodies (ACPAs) were reported to be
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systems for anti-cyclic citrullinated peptide (CCP) anti-
bodies have been improved, and the sensitivity and spe-
cificity of anti-CCP antibodi e si nt h ed i a g n o s i so fR A
are 60%-80% and 95%-98%, respectively [5,6]. Impor-
tantly, anti-CCP antibodies are detected several years
before joint inflammation is observed [7,8]. Due to the
high specificity of ACPAs in RA, their role in the patho-
genesis of RA has become the focus of active
investigation.
ACPAs were first described as anti-rat esophageal
antibodies, and Girbal-Neuhauser et al. discovered that
citrullinated filaggrin was a target antigen of those anti-
bodies [3]. Although citrullinated filaggrin is not present
in the inflammatory synovium of RA patients, several
citrullinated auto-antigens, including citrullinated fibri-
nogen, vimentin, type II collagen, and alpha-enolase,
have been reported as target antigens of ACPAs in the
synovia of RA patients [9-14]. In one hypothesis for the
pathogenesis of RA, ACPAs bind to these citrullinated
auto-antigens in the synovial tissues and form immune
complexes that induce inflammatory processes [15].
Once synovial inflammation occurs, apoptosis and pro-
tein citrullination are induced. The continuous produc-
tion of ACPAs and immune complexes results in
sustained joint inflammation [16]. Indeed, serum C1q-
binding immune complexes isolated from RA patients
contained citrullinated fibrinogen [17], and immuniza-
tion of citrullinated fibrinogen induced inflammatory
arthritis in HLA-DR4 transgenic mice [18]. However,
the mechanisms by which ACPAs develop and synovial
proteins are citrullinated in humans remain unclear.
Furthermore, the causes of RA remain unclear; it is sug-
gested that genetic and environmental factors could
cause RA, and several genetic risk factors have recently
been determined. Importantly, single nucleotide poly-
morphisms in the peptidylarginine deaminase, type IV
(PADI4) gene, which encodes a key enzyme for protein
citrullination, are associated with RA susceptibility [19].
Therefore, auto-antigen citrullination and ACPA devel-
opment are considered as important steps in the patho-
genesis of RA.
The presence of serum anti-immunoglobulin binding
protein (BiP) antibodies has been reported in RA sera,
and anti-BiP antibodies showed similar sensitivity and
specificity as RF [20,21]. BiP is a member of the heat
shock protein 70 family and is expressed in the endo-
plasmic reticulum. It functions as a molecular chaperone
and can bind to many proteins. BiP concentrations are
elevated in the synovial fluid of RA patients [21], and
BiP-responsive T cells are also detected in RA patients
[22]. Here, we described the detection of anti-citrulli-
nated BiP (citBiP) antibodies in the serum of RA
patients. An epitope mapping study revealed that several
citrulline residues were recognized by anti-citBiP antibo-
dies. In a mouse study, we obse r v e dt h a ti m m u n i z a t i o n
with citBiP induced ACPAs, including anti-CCP and
anti-citrullinated fibrinogen antibodies. In addition, col-
lagen-induced arthritis (CIA) was exacerbated by pre-
immunization with citBiP. Therefore, we concluded that
citBiP is a newly determined target of ACPAs and that
it is closely related to the pathogenesis of inflammatory
arthritis.
Materials and methods
Patients
Serum samples were obtained from 100 RA patients, 60
systemic lupus erythematosus (SLE) patients, and 30
healthy volunteers. All of the RA patients fulfilled the
1987 and 2010 American College of Rheumatology cri-
teria for RA [23,24]. SLE diagnosis was made according
to the diagnostic criteria of the American College of
Rheumatology [25,26]. Written informed consent was
obtained before blood samples were taken. This study
was approved by the ethics committee of Tokyo Univer-
sity Hospital.
Mice
DBA/1J female mice (age: 6-8 weeks) were obtained
from SLC Japan (Shizuoka, Japan). All animal experi-
ments were conducted in accordance with institutional
and national guidelines.
Antigens and peptides
A full-length fragment of mouse BiP cDNA (GenBank:
AJ002387) was subcloned, and the plasmid vector,
which contained a mouse BiP cDNA sequence with a
His
6-tag at its N-terminal, was prepared using a Cham-
pion pET Directional TOPO Expressing Kit (K100-01;
Invitrogen, Carlsbad, CA, USA). The vector was trans-
duced into BL21 Star One Shot Chemically Competent
Escherichia coli (Invitrogen) by using a heat shock pro-
cedure. The transformed BL21 E. coli were incubated in
LB medium with ampicillin (100 μg/mL). When the
absorbance (O.D. 650 nm) rose to 0.5, 1 mM of isopro-
pylthio-beta-galactoside (Invitrogen) was added to the
medium. After a 6 h incubation, the pellet was dissolved
using the Fast Break Cell Lysis Reagent (Promega, Madi-
son, WI, USA) and the lysate was purified using an Ni-
NTA Fast Start Kit (QIAGEN, Valencia, CA, USA)
according to the manufacturer’s procedure. Mouse fibri-
nogen was purchased from Sigma-Aldrich (St. Louis,
MO, USA). For endotoxin removal, purified proteins
were passed through a Detoxi-Gel AffinityPak prepared
column (Pierce, Rockford, IL, USA) according to the
manufacturer’s protocol.
For protein citrullination, 2 U of rabbit PADI2
(Sigma-Aldrich) were added to 1 mg of the protein in
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DTT) at 37°C for 2 h. EDTA (20 mM) was added to
stop the reaction [15]. The samples were then passed
through the Ni-NTA column to remove PADI2.
The peptides (Tables 1 and 2) were synthesized using
NeoMPS (San Diego, CA, USA). Native BiP-derived
peptides were also prepared that covered the entire
human BiP sequence (GenBank: CAA61201) (Table 1).
BiP includes 27 arginine residues that could be
replaced by citrulline; therefore, we designed 27
synthesized peptides that each contained 1 citrulline
residue (Table 2). In some experiments, we also pre-
pared original peptides without citrullination. Peptide
purity was >80%.
Immunization of mice
Murine BiP and citBiP were emulsified with an equal
volume of complete Freund’s adjuvant (CFA) (Chon-
d r e x ,R e d m o n d ,W A ,U S A ) ,a n dD B A / 1 Jm i c ew e r e
immunized with 100 μg of murine BiP or citBiP intra-
dermally at the tail base. Spleen samples for culture
were obtained at 14 days post-immunization and serum
samples for antibody titer measurements were obtained
at 28 days post-immunization.
Table 1 Synthetic peptides derived from native human
BiP protein
Number Amino acid sequences Position
BiP1 EDKKEDVGTVVGIDLGTTYS 21-40
BiP2 GTTYSCVGVFKNGRVEIIAN 36-55
BiP3 EIIANDQGNRITPSYVAFTP 51-70
BiP4 VAFTPEGERLIGDAAKNQLT 66-85
BiP5 KNQLTSNPENTVFDAKRLIG 81-100
BiP6 KRLIGRTWNDPSVQQDIKFL 96-115
BiP7 DIKFLPFKVVEKKTKPYIQV 111-130
BiP8 PYIQVDIGGGQTKTFAPEEI 126-145
BiP9 APEEISAMVLTKMKETAEAY 141-160
BiP10 TAEAYLGKKVTHAVVTVPAY 156-175
BiP11 TVPAYFNDAQRQATKDAGTI 171-190
BiP12 DAGTIAGLNVMRIINEPTAA 186-205
BiP13 EPTAAAIAYGLDKREGEKNI 201-220
BiP14 GEKNILVFDLGGGTFDVSLL 216-235
BiP15 DVSLLTIDNGVFEVVATNGD 231-250
BiP16 ATNGDTHLGGEDFDQRVMEH 246-265
BiP17 RVMEHFIKLYKKKTGKDVRK 261-280
BiP18 KDVRKDNRAVQKLRREVEKA 276-295
BiP19 EVEKAKRALSSQHQARIEIE 291-310
BiP20 RIEIESFYEGEDFSETLTRA 306-325
BiP21 TLTRAKFEELNMDLFRSTMK 321-340
BiP22 RSTMKPVQKVLEDSDLKKSD 336-355
BiP23 LKKSDIDEIVLVGGSTRIPK 351-370
BiP24 TRIPKIQQLVKEFFNGKEPS 366-385
BiP25 GKEPSRGINPDEAVAYGAAV 381-400
BiP26 YGAAVQAGVLSGDQDTGDLV 396-415
BiP27 TGDLVLLDVCPLTLGIETVG 411-430
BiP28 IETVGGVMTKLIPRNTVVPT 426-445
BiP29 TVVPTKKSQIFSTASDNQPT 441-460
BiP30 DNQPTVTIKVYEGERPLTKD 456-475
BiP31 PLTKDNHLLGTFDLTGIPPA 471-490
BiP32 GIPPAPRGVPQIEVTFEIDV 486-505
BiP33 FEIDVNGILRVTAEDKGTGN 501-520
BiP34 KGTGNKNKITITNDQNRLTP 516-535
BiP35 NRLTPEEIERMVNDAEKFAE 531-550
BiP36 EKFAEEDKKLKERIDTRNEL 546-565
BiP37 TRNELESYAYSLKNQIGDKE 561-580
BiP38 IGDKEKLGGKLSSEDKETME 576-595
BiP39 KETMEKAVEEKIEWLESHQD 591-610
BiP40 ESHQDADIEDFKAKKKELEE 606-625
BiP41 KELEEIVQPIISKLYGSAGP 621-640
BiP42 GSAGPPPTGEEDTAELHHHH 636-655
BiP = immunoglobulin-binding protein.
Table 2 Synthetic peptides
Number Amino acid sequences Position
1 YSCVGVFKNG(Cit)VEIIANDQG 39-58
2 VEIIANDQGN(Cit)ITPSYVAFT 50-69
3 SYVAFTPEGE(Cit)LIGDAAKNQ 64-83
4 NPENTVFDAK(Cit)LIGRTWNDP 87-106
5 TVFDAKRLIG(Cit)TWNDPSVQQ 91-110
6 TVPAYFNDAQ(Cit)QATKDAGTI 171-190
7 AGTIAGLNVM(Cit)IINEPTAAA 187-206
8 AAAIAYGLDK(Cit)EGEKNILVF 204-223
9 THLGGEDFG(Cit)VMEHFIKLY 251-270
10 LYKKKTGKDV(Cit)KDNRAVQKL 269-288
11 KTGKDVRKDN(Cit)AVQKLRREV 273-292
12 RKDNRAVQKL(Cit)REVEKAKRA 279-298
13 KDNRAVQKLR(Cit)EVEKAKRAL 280-299
14 KLRREVEKAK(Cit)ALSSQHQAR 287-306
15 AKRALSSQHQA(Cit)IEIESFFE 295-314
16 FEGEDFSETLT(Cit)AKFEELNM 313-332
17 AKFEELNMDLF(Cit)STMKPVQK 325-344
18 IDEIVLVGGST(Cit)IPKIQQLV 356-375
19 VKEFFNGKEPS(Cit)GINPDEAV 375-394
20 TVGGVMTKLIP(Cit)NTVVPTKK 428-447
21 TVTIKVYEGE(Cit)PLTKDNHLL 460-479
22 FDLTGIPPAP(Cit)GVPQIEVTF 482-501
23 TFEIDVNGIL(Cit)VTAEDKGTG 500-519
24 NKITITNDQN(Cit)LTPEEIERM 522-541
25 QNRLTPEEIE(Cit)MVNDAEKFA 530-549
26 FAEEDKKLKE(Cit)IDTRNELES 548-567
27 EDKKLKERIDT(Cit)NELESYAYS 551-570
11R KTGKDVRKDNRAVQKLRREV 273-292
12R RKDNRAVQKLRREVEKAKRA 279-298
15R AKRALSSQHQARIEIESFFE 295-306
23R TFEIDVNGILRVTAEDKGTG 500-519
Cit: citrulline residue.
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The serum levels of the anti-CCP antibodies were mea-
sured using MESACUP FCCP200 (Axis-Shield Diagnos-
tics Ltd., Dundee, UK). Anti-CCP antibodies in the
human serum samples were measured according to the
manufacturer’s protocol. Goat anti-mouse IgG-alkaline
phosphate (Chemicon, Temecula, CA, USA) was used at
a 3000-fold dilution as the detection antibody for mea-
suring mouse serum anti-CCP antibodies [15]. In the
competitive assay, the indicated concentrations of citrul-
linated peptides were added to human anti-CCP anti-
body-positive standard serum samples (a mixture of
serum from 18 ACPA-positive RA patients), the samples
were incubated for 2 h at room temperature, and the
anti-CCP antibody levels were then measured.
To detect antibodies to other proteins, 5 μg/mL of each
antigen was dissolved in 0.1 M NaHCO3 and 100 μLo f
each were plated in 96-well plates (Immuron4 Multiplate;
Dynatech Laboratories, Chantilly, VA, USA) at 4°C for 16
h. After the plates were blocked using PBS containing 3%
skimmed milk and 0.5% Tween-20, ×100 diluted samples
were applied. Goat anti-human IgG-horseradish peroxi-
dase (HRP) (Vector, Burlingame, CA, USA) or goat anti-
mouse IgG-HRP antibodies (Zymed, South San Fran-
cisco, CA, USA) were used at a 5000-fold dilution as
detection antibodies and TMB solution (KPL, Gaithers-
burg, MD, USA) was used to develop the colors. An
automatic microplate reader (Bio-Rad 550; Bio-Rad, Her-
cules, CA, USA) was used to measure optical density.
Immunoblotting
After 1 μg BiP or citBiP was electrophoresed using
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis, the samples were blotted to Hybond ECL (GE
Healthcare). The membranes were blocked with PBS
c o n t a i n i n g1 0 %s k i m m e dm i l ka tr o o mt e m p e r a t u r ef o r
1 h and ×100 diluted serum samples were then applied
at 4°C for 16 h. A goat anti-human IgG-HRP antibody
was used at a 5000-fold dilution as the detection anti-
body. The membranes were treated with ECL reagent
(GE Healthcare, Buckinghamshire, UK) and the film
images were developed. A polyclonal rabbit anti-BiP
antibody (Thermo Fisher Scientific, Rockford, IL, USA)
was used at a 100-fold dilution as a positive control. A
Senshu antibody (rabbit polyclonal anti-modified citrul-
line antibody; Upstate Biochemicals, Lake Placid, NY,
USA) was used to detect the citrullinated antigens, and
blotting was performed in accordance with the manufac-
turer’s protocol [27]. Band density was quantified using
NIH ImageJ software.
Immunofluorescence assay
Rat esophageal sections (SCIMEDX Corporation, Den-
ville, NJ, USA) were used, and citrullinated filaggrin was
detected according to the manufacturer’sp r o t o c o l .I n
short, mouse serum samples were treated at room tem-
perature for 1 h and Alexa Fluor 488-conjugated goat
anti-mouse IgG antibody (Invitrogen) was used as the
detection antibody. The samples were observed under a
fluorescent microscope [15].
Collagen-induced arthritis
CIA was induced as described previously [28]. In short,
bovine type II collagen (Chondrex) was emulsified with
an equal volume of CFA or incomplete Freund’sa d j u -
vant (IFA) (Chondrex). Fourteen days after immuniza-
tion with BiP or citBiP, DBA/1J mice were immunized
with 50 μg bovine type II collagen intradermally at the
tail base on day 14 with CFA and on day 35 with IFA.
T h ea r t h r i t i ss c o r ew a sd e t e r m i n e db yt h ed e g r e eo f
erythema, swelling, or ankylosis observed on each paw,
as described elsewhere [29]. The mice were sacrificed at
50 days after the first CIA immunization. Tissue sam-
ples were embedded in paraffin wax after 10% formalde-
hyde fixation and decalcification. The sections were
stained with hematoxylin and eosin. Synovial tissues
were graded by mononuclear cell infiltration, pannus
formation, and cartilage erosion, as described previously
[30].
Statistical analysis
All values are expressed as the median. Differences were
compared using the Mann-Whitney U test. Correlations
between the levels of two antibodies were analyzed by
the Spearman correlation coefficient. Graphpad Prism 5
was used for statistical analysis. P-values < 0.05 were
considered significant.
Results
Anti-citBiP antibodies in the serum of RA patients
We first measured the serum levels of anti-BiP and anti-
citBiP antibodies in RA patients, SLE patients, and
healthy controls (Figure 1A). Among these patients, 95
RA patients and no SLE patients were positive for anti-
CCP antibodies. We chose SLE patients as disease con-
trols because ~30% of SLE patients are positive for anti-
BiP antibodies, while serum anti-CCP antibodies are
detected in <5% of SLE patients [31]. In RA patients,
the levels of anti-BiP and anti-citBiP antibodies were
significantly higher than those observed in SLE patients
and healthy controls (p < 0.001). Immunoblotting analy-
sis demonstrated higher serum concentrations of anti-
citBiP antibodies than anti-BiP antibodies in the serum
of each anti-CCP antibody-positive RA patient (Figure
1B). Seventy-two percent of RA patients showed higher
anti-citBiP antibody levels than anti-BiP antibody levels,
whereas there was no significant difference in the serum
titers of anti-BiP and anti-citBiP antibodies in the non-
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Figure 1 Serum anti-citrullinated BiP (citBiP) antibodies were detected in rheumatoid arthritis (RA) patients at a high frequency, but
not in systemic lupus erythematosus (SLE) patients or healthy controls. A. Comparison of the levels of anti-BiP and citBiP antibodies in
healthy controls (n = 30), SLE patients (n = 60), and RA patients (n = 100). The serum levels of anti-BiP and citBiP antibodies were measured by
ELISA. **: P < 0.01. B. Immunoblotting of the representative serum samples from anti-citBiP antibody-positive RA patients. AMC stands for anti-
modified citrulline antibody (Senshu antibody). Band densities were quantified by ImageJ, and the fold increase is indicated. C. The difference
between the serum levels of anti-citBiP and anti-BiP antibodies in the serum of RA patients and non-RA controls. ***: P < 0.001. D. Correlation
between anti-CCP and anti-BiP/citBiP antibodies. E. Epitope mapping of anti-BiP antibodies. The serum levels of antibodies to native BiP-derived
peptides. The sequences of the native BiP-derived peptides are shown in Table 2. The serum samples were taken from anti-BiP antibody-positive
RA patients (n = 15, closed circles) and healthy controls (n = 5, open circles). The horizontal lines indicate medians. P-values were calculated by
Mann-Whitney U test.
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that serum anti-BiP antibodies were detected in SLE
patients [31]; in our study, the serum levels of anti-BiP
and anti-citBiP antibodies in SLE patients were mildly
increased in comparison with those in healthy controls
(p < 0.05) (Figure 1A). However, in contrast to RA,
there was no significant difference in the serum levels of
anti-BiP and anti-citBiP antibodies in SLE patients (Fig-
ure 1C). In RA patients, the serum levels of anti-citBiP
antibodies were strongly correlated with those of anti-
CCP antibodies (R
2 = 0.59), whereas the levels of anti-
BiP antibodies were less correlated with those of anti-
CCP antibodies (R
2 = 0.38) (Figure 1D). Therefore, the
serum levels of anti-citBiP antibodies are higher than
those of anti-BiP antibodies and have a clear association
with anti-CCP antibodies in RA patients.
Because BiP is an immunoglobulin chaperon protein,
there is the possibility that immunoglobulins bind to
BiP, independent of epitope recognition by the antigen-
binding site. To confirm the existence of specific epitope
recognition, epitope mapping was performed by using
native human BiP-derived peptides. The mapping
revealed that BiP1 (BiP21-40), BiP16 (BiP246-265), BiP39
(BiP591-610), BiP40 (BiP606-625), and BiP42 (BiP636-655)
were the epitopes recognized by the anti-BiP antibodies
(Figure 1E). Most of these major epitopes were located
in the C and N terminals. Therefore, anti-human BiP
antibodies truly exist in the serum of RA patients.
Determination of the citrullinated epitopes of anti-citBiP
antibodies
To identify the citrullinated epitopes of the anti-citBiP
antibodies in RA, we prepared citrullinated peptides in
which the arginine residues of the native BiP sequences
were replaced with citrulline residues. Serum antibody
levels to each of the citBiP-derived peptides were mea-
sured in RA patients with high anti-citBiP antibody
levels (n = 18) and healthy controls (n = 5). The serum
antibody levels were increased against several citrulli-
nated peptides (Figure 2A). Four of the major citBiP-
derived epitopes were selected for further investigation,
and the serum levels of the anti-native peptide antibo-
dies and the anti-citrullinated peptide antibodies were
compared (Figure 2B). The serum antibody levels to
No. 12 (BiP279-298 R289citrulline), 15 (BiP295-314
R305citrulline), and 23 (BiP500-519 R510citrulline) citrul-
linated peptides were significantly increased compared
with those of the native peptides in RA patients. Thus,
these citrullinated residues were thought to be impor-
tant residues for autoantibody recognition in RA. Thus,
the positions of the major citrullinated epitopes (BiP279-
298,B i P 295-314,a n dB i P 500-519) were different from the
major epitopes of the native BiP protein (BiP21-40,
BiP246-265,B i P 591-610,B i P 604-625,a n dB i P 636-655). In
particular, the No. 23 citrullinated peptide inhibited
serum antibody binding to CCP, whereas the No. 22
peptide did not (Figure 2C). No. 12 and 15 citrullinated
peptides did not bind to CCP either (data not shown).
Therefore, we identified several citrullinated anti-citBiP
antibody epitopes, one of which showed a clear cross-
reaction with CCP.
Induction of ACPAs in citBiP-immunized mice
We then examined whether active immunization with
citBiP could induce ACPAs in a mouse model. DBA/1J
mice were immunized with BiP or citBiP and serum
samples were obtained after 28 days. Anti-CCP antibo-
dies were detected in the serum samples of citBiP-
immunized mice (Figure 3A). Although BiP immuniza-
tion also induced the development of anti-CCP antibo-
dies, the anti-CCP antibody levels were relatively low.
Because Vossenaar et al. pointed out that some mouse
models of inflammatory arthritis developed false-positive
anti-CCP antibodies [32], we verified the presence of
ACPAs using different methods. The serum levels of
anti-citrullinated fibrinogen antibodies were only
detected in the sera of citBiP-immunized mice (Figure
3B). We stained rat esophageal horny layer containing
citrullinated filaggrin with sera from citBiP-immunized
mice (Figure 3C). Therefore, we confirmed that citBiP
immunization not only induced anti-citBiP antibodies
but also induced other ACPAs.
Exacerbation of CIA by pre-immunization with citBiP
Finally, we tested the pro-inflammatory effects of citBiP
in the CIA mouse model. Similar to the findings in RA,
CIA mouse sera contained anti-BiP and anti-citBiP anti-
bodies (Figure 4A). The serum levels of anti-citBiP anti-
bodies were higher than those of anti-BiP antibodies.
Since the development of ACPAs precedes the onset of
RA, some immune responses to citrullinated antigens
are hypothesized to occur before RA becomes clinically
obvious. We assessed this hypothesis by pre-immunizing
mice with citBiP before inducing CIA, and determined
whether the immune responses to citBiP were associated
with the enhancement of inflammatory arthritis. Four-
teen days after BiP or citBiP immunization, the mice
were immunized with bovine type II collagen to induce
arthritis. Joint inflammation developed sooner and was
significantly exacerbated in the citBiP-pre-immunized
mouse group as compared to the control group (Figure
4B and Additional file 1). BiP-pre-immunized mice did
not develop severe arthritis. There was a significant
increase in the histological scores of the citBiP-pre-
i m m u n i z e dm o u s eg r o u p( F i g u r e4 C ) .T h es e r u ml e v e l s
of anti-CCP antibodies were also significantly elevated
in the citBiP-pre-immunizedm i c e( F i g u r e4 D ) .T h e r e -
fore, citBiP immunization exacerbated inflammatory
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Page 7 of 12arthritis in mice, whereas BiP immunization had no sig-
nificant effect on CIA.
Discussion
BiP is a molecular chaperone that is expressed in the
endoplasmic reticulum and a known RA auto-antigen.
BiP is overexpressed in the synovial fluids of RA patients,
and anti-BiP antibodies develop in 60% of RA patients
[20,21]. CD8
+ T cells from the peripheral blood of RA
patients respond to BiP stimulation and release cytokines
such as interleukin (IL)-10 [22]. In inflammatory arthritis
mouse models, the intravenous administration of BiP
ameliorated joint inflammation, and the Th2 cytokine IL-
4 was associated with these anti-inflammatory effects
[33]. Although some reports showed that BiP induces
anti-inflammatory T cells that produce IL-4 and IL-10,
pro-inflammatory responses to BiP were also observed.
BiP-stimulated human peripheral blood mononuclear
cells secreted tumor necrosis factor (TNF)-ε in the early
phase [34], and mouse BiP-primed T cells simultaneously
produced interferon-g [33]. In fact, anti-BiP antibodies
develop in RA patients, form immune complexes, and
induce inflammatory processes in the synovium. Thus,
the role of BiP in the pathogenesis of RA is controversial.
In the present study, we demonstrated that citBiP is a
new target of RA autoantibodies and that the serum
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Figure 3 Immunization of citBiP induced anti-citrullinated protein/peptide antibodies in mice. Immunized citBiP was prepared in the
same way as the one shown in Figure 1B. A. Serum levels of anti-CCP antibodies in control, complete Freund’s adjuvant (CFA)-immunized, BiP
+CFA-immunized, and citBiP+CFA-immunized mice. B. Serum levels of anti-fibrinogen and anti-citrullinated fibrinogen antibodies in control and
immunized mice. **: P < 0.01. C. Immunofluorescence assay of mouse serum to the rat esophageal horny layer (arrows). The horizontal lines
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Page 8 of 12levels of anti-citBiP antibodies are higher in RA patients
than those of anti-BiP antibodies. We performed B cell
epitope mapping of BiP and citBiP. B cell epitope map-
ping using linear peptides sometimes misses discontinu-
ous epitopes, which are recognized by antibodies only in
the native conformation. Nevertheless, this protocol is
good at identifying continuous epitopes, which are
formed from single short peptide strands constructed on
a generally linear backbone structure. In our study, the
locations of the major epitopes of the anti-citBiP antibo-
dies were clearly different from those of the anti-native
BiP antibodies. Despite the limitation of using linear
peptides for epitope mapping, these data suggested that
the anti-citBiP and anti-BiP antibodies are produced via
different processes in RA patients. In addition, there was
no significant difference between the serum levels of
anti-BiP and anti-citBiP antibodies in SLE patients, sug-
gesting that the development of anti-citBiP antibodies
was a distinct process in RA.
In the mouse model, citBiP immunization induced
higher anti-CCP antibody levels than BiP immunization.
Furthermore, citBiP pre-immunization exacerbated
inflammatory arthritis, whereas BiP pre-immunization
had no significant effects on CIA. Therefore, we believe
that citBiP is more arthrogenic than BiP and could play
an important role in the pathogenesis of inflammatory
arthritis. In this context, the existence and localization
of citBiP are important questions. Some reports have
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Page 9 of 12shown that BiP was overexpressed in the inflamed syno-
vial tissues of RA patients [20,21]. Although citrullinated
BiP was not detected in the synovial exosomes of RA
patients [35], Lu et al. recently reported that citBiP was
expressed on macrophage membranes, a target of
ACPAs [36]. They also demonstrated that ACPAs could
bind to citBiP on macrophage surfaces to induce the
secretion of TNF-ε. Therefore, it is possible that macro-
phage membrane-bound citBiP is a source of the citrul-
linated protein in some situations.
The role of protein citrullination in the pathogenesis
of RA has been widely investigated, and some reports
explained the role of protein citrullination in the
immune system. First, protein citrullination modifies the
electric charge, i.e., arginine is positively charged, while
citrulline is neutral. This electric change may result in a
structural change of the protein and reveal hidden epi-
topes [37]. Other groups have reported that protein
citrullination itself reinforced antigenicity and induced
more intense immune responses. The citrullinated auto-
antigens possessed enough antigenicity to break immune
tolerance to the auto-antigens [18,38]. In our data, cit-
BiP immunization induced several kinds of ACPAs and
exacerbated arthritis. We suppose that the pre-induction
of anti-CCP antibodies could explain this pro-arthritis
effect of citBiP immunization. However, the precise role
of anti-CCP antibodies in mice remains unclear.
Although more observations are necessary to demon-
strate how the preceding immune responses to citBiP
exacerbate CIA, these studies suggested the reason why
t h ei m m u n er e s p o n s e st oc i tBiP were different from
those to BiP in RA patients and our mouse model.
In the mouse study, we demonstrated that citBiP-
immunization could induce several ACPAs. One possi-
ble explanation is epitope spreading. Epitope spreading
has been demonstrated in a variety of spontaneous and
induced autoimmune diseases, such as experimental
autoimmune encephalitis and diabetes in NOD mice
[38,39]. A recent study showed that epitope spreading of
ACPAs was observed in RA patients [40]. In our mouse
study, immunization with citBiP could induce antibody
responses to other citrullinated proteins, such as citrulli-
nated fibrinogen and filaggrin. The pivotal role of B
cells in epitope spreading has been proposed because B
cells are very efficient antigen-presenting cells or anti-
gens that are taken up specifically through the B-cell
receptor [41]. On the basis of the fact that different
ACPA responses are cross-reactive [42], one hypothesis
suggests that B cells expressing the B-cell receptor spe-
cific to citBiP could uptake and present several kinds of
citrullinated proteins other than citBiP. The immune
response to citBiP immunization could be a good model
to study how the development of several ACPAs occurs,
although more examinations are required.
With regard to the majority of target proteins for
ACPA, including fibrinogen, vimentin, and alpha-eno-
lase, antibodies react only with the citrullinated forms of
these molecules and not with their native forms. In
sharp contrast, antibodies to native BiP are readily
detected in RA patients [20,21]. In this study, immuniza-
tion with BiP also induced low anti-CCP antibody titers.
Ireland et al. suggested that APCs could present citrulli-
nated peptides even when given an unmodified protein
[43], which could be an explanation for this phenom-
enon. Nonetheless, subcutaneous pre-immunization with
BiP coupled with adjuvant induced no significant effects
on CIA development in our experiments. These results
s u g g e s tt h a ta ni m m u n er e s p o n s et ot h en a t i v ef o r mo f
BiP is not sufficient for the progression of arthritis and
that a significant level of immunity against citBiP is
required. However, immunity to BiP and citBiP may
augment the production of other ACPAs in RA.
Conclusions
In conclusion, we demonstrated that anti-citBiP antibo-
dies appeared in the sera of RA patients. Because the
serum levels of anti-citBiP antibodies were higher than
those of anti-BiP antibodies in 72% of RA patients, and
the location of the major epitopes of anti-citBiP and
anti-BiP antibodies were different in RA patients, the
development of anti-citBiP antibodies can be a distinct
process in the pathogenesis of RA. In our mouse study,
immunization with citBiP induced several kinds of
ACPAs, including anti-CCP and anti-citrullinated fibri-
nogen antibodies. Furthermore, pre-immunization with
citBiP exacerbated CIA. Therefore, we concluded that
citBiP could play an important role in the pathogenesis
of inflammatory arthritis and could be a new diagnostic
and therapeutic target for RA.
Additional material
Additional file 1: The arthritis scores for the other 2 sets of trials in
collagen-induced arthritis (CIA) mice that were pre-immunized with
complete Freund’s adjuvant (CFA), BiP+CFA, or citBiP+CFA (n = 10
each).* :P < 0.05.
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